WO2013181251A1 - Crizotinib hydrochloride salt in crystalline - Google Patents

Crizotinib hydrochloride salt in crystalline Download PDF

Info

Publication number
WO2013181251A1
WO2013181251A1 PCT/US2013/043113 US2013043113W WO2013181251A1 WO 2013181251 A1 WO2013181251 A1 WO 2013181251A1 US 2013043113 W US2013043113 W US 2013043113W WO 2013181251 A1 WO2013181251 A1 WO 2013181251A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
crizotinib
theta
degrees
ray powder
crystalline form
Prior art date
Application number
PCT/US2013/043113
Other languages
French (fr)
Other versions
WO2013181251A9 (en )
Inventor
Simone EICHNER
Wolfgang Albrecht
Richard Guserle
Frank Lehmann
Original Assignee
Ratiopharm Gmbh
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present invention provides salts of Crizotinib, solid state forms thereof, and pharmaceutical compositions comprising at least one of the salts or solid state forms. The invention includes crystalline forms of Crizotinib hydrochloride salt.

Description

CRIZOTINIB HYDROCHLORIDE SALT IN CRYSTALLINE

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Nos. 61/652,708, filed May 29, 2012; and 61/752,673; filed January 15, 2013, the contents of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

The present invention encompasses Crizotinib salts, solid state forms thereof, and pharmaceutical compositions comprising the Crizotinib salts and solid state forms thereof.

BACKGROUND OF THE INVENTION

Crizotinib, (i?)-3-[l-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine, having the following formula

Figure imgf000002_0001
is an orally active dual inhibitor of mesenchymal epithelial transition growth factor (c-Met) and anaplastic lymphoma kinase (ALK). It was developed for the treatment of cancer.

Crizotinib, as well as certain pharmaceutically acceptable salts thereof, is described in WO2006/021881 and WO2006/021884. WO2007/066185 describes a crystalline form of the Crizotinib base.

Different salts and solid state forms of an active pharmaceutical ingredient may possess different properties. Such variations in the properties of different salts and solid state forms may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, improving the dissolution profile, or improving stability (polymorph as well as chemical stability) and shelf-life. These variations in the properties of different salts and solid state forms may also provide improvements to the final dosage form, for instance, if they serve to improve bioavailability. Different salts and solid state forms of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms, which may in turn provide additional opportunities to assess variations in the properties and characteristics of a solid active pharmaceutical ingredient.

Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g. measured by thermogravimetric analysis - "TGA", or differential scanning calorimetry - "DSC"), X-ray diffraction pattern, infrared or Raman absorption fingerprint, and solid state 13C-NMR spectrum. One or more of these techniques may be used to distinguish different polymorphic forms of a compound.

Discovering new salts and solid state forms of a pharmaceutical product can provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms. New salts and solid state forms (including solvated forms) of a pharmaceutically useful compound can also provide an opportunity to improve the performance characteristics of a pharmaceutical product (dissolution profile,

bioavailability, etc.). It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, e.g., different crystal habit, higher crystallinity or polymorphic stability which may offer better processing or handling characteristics, improved dissolution profil, or improved shelf-life. For at least these reasons, there is a need for additional salts and solid state forms of Crizotinib.

SUMMARY OF THE INVENTION

The present invention provides salts of Crizotinib, solid state forms thereof, and pharmaceutical compositions comprising at least one of the salts or solid state forms.

The present invention provides Crizotinib phosphate, Crizotinib sulphate, Crizotinib acetate, Crizotinib maleate, Crizotinib fumarate, Crizotinib L-tartrate, Crizotinib citrate, Crizotinib p-toluene sulfonate, Crizotinib succinate, Crizotinib formate, Crizotinib hydrochloride, Crizotinib besilate, Crizotinib ethane- 1,2-disulfonate and Crizotinib L-malate. These salts of Crizotinib can be obtained in solid sate forms. Accordingly, the present invention provides amorphous as well as crystalline forms of these salts.

The present invention also encompasses the use of any one of the Crizotinib salts and solid state forms of the present invention for the preparation of other Crizotinib salts, Crizotinib base, other solid state forms of Crizotinib base or Crizotinib salt, and

pharmaceutical compositions comprising salts of Crizotinib or solid state forms thereof.

The present invention also provides processes for preparing Crizotinib base by preparing any one of the Crizotinib salts and solid state forms of the present invention and converting it to Crizotinib base. Particularly, the present invention provides processes for preparing Crizotinib base, wherein the processes comprise preparing any one of Crizotinib phosphate, Crizotinib sulphate, Crizotinib acetate, Crizotinib maleate, Crizotinib fumarate, Crizotinib L-tartrate, Crizotinib citrate, Crizotinib p-toluene sulfonate, Crizotinib succinate, Crizotinib formate, Crizotinib Hydrochloride, Crizotinib besilate, Crizotinib ethane- 1,2- disulfonate and Crizotinib L-malate, and converting it to Crizotinib base.

The present invention also encompasses the Crizotinib salts and solid state forms described herein for use as medicaments, particularly medicaments for the treatment of cancer.

The present invention further provides pharmaceutical compositions comprising at least one of the Crizotinib salts and solid state forms thereof of the present invention. The invention also provides pharmaceutical formulations, comprising at least one of the

Crizotinib salts and solid state forms thereof as described herein, and at least one

pharmaceutically acceptable excipient.

The pharmaceutical compositions and formulations can be used as medicaments, in particular medicaments for treating cancer. Examples of the formulations include, but are not limited to, tablets or capsules comprising the pharmaceutical compositions.

The present invention comprises a process for preparing the above mentioned pharmaceutical formulations. The process comprises combining at least one of the Crizotinib salts and solid state forms thereof of the present invention or the pharmaceutical composition, with at least one pharmaceutically acceptable excipient. The present invention also provides methods of treating cancer, particularly cancers mediated by mesenchymal epithelial transition growth factor (c-Met) or anaplastic lymphoma kinase (ALK). The methods comprise administering a therapeutically effective amount of at least one of the Crizotinib salts and solid state forms thereof of the present invention, or at least one of the above pharmaceutical compositions or formulations to a person suffering from cancer or otherwise in need of the treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows Background X-ray powder diffractogram after analysis of the silicon specimen holder. Figure 2 shows ^-NMR spectrum of crizotinib phosphate.

Figure 3 shows X-ray powder diffractogram of Crizotinib phosphate - amorphous Form PI.

Figure 4 shows ^-NMR spectrum of crizotinib sulphate.

Figure 5 shows X-ray powder diffractogram of crizotinib sulphate - crystalline Form SI (procedure 1 - methanol).

Figure 6 shows DSC thermogram of crizotinib sulphate - crystalline Form SI.

Figure 7 shows X-ray powder diffractogram of crizotinib sulphate - amorphous Form

S2.

Figure 8 shows ^-NMR spectrum of Crizotinib acetate. Figure 9 shows X-ray powder diffractogram of Crizotinib acetate - Form Al .

Figure 10 shows X-ray powder diffractogram of Crizotinib acetate - crystalline Form

A2.

Figure 11 shows DSC thermogram of Crizotinib acetate - crystalline Form A2. Figure 12 shows X-ray powder diffractogram of Crizotinib acetate - amorphous Form A3.

Figure 13 shows ^-NMR spectrum of crizotinib succinate. Figure 14 shows X-ray powder diffractogram of Crizotinib succinate - amorphous Form SAL

Figure 15 shows ^-NMR spectrum of crizotinib maleate.

Figure 16 shows X-ray powder diffractogram of Crizotinib maleate - crystalline Form Ml.

Figure 17 shows ^-NMR spectrum of crizotinib fumarate.

Figure 18 shows X-ray powder diffractogram of Crizotinib fumarate - Form Fl.

Figure 19 shows X-ray powder diffractogram of Crizotinib fumarate - crystalline Form F2. Figure 20 shows ^-NMR spectrum of crizotinib tartrate.

Figure 21 shows X-ray powder diffractogram of Crizotinib tartrate - crystalline Form

Tl.

Figure 22 shows X-ray powder diffractogram of Crizotinib tartrate - amorphous Form

T2. Figure 23 shows ^-NMR spectrum of crizotinib citrate.

Figure 24 shows X-ray powder diffractogram of Crizotinib citrate - amorphous Form

CI.

Figure 25 shows ^-NMR spectrum of crizotinib p-toluene sulphonate.

Figure 26 shows X-ray powder diffractogram of Crizotinib p-toluene sulphonate - Form Tsl.

Figure 27 shows 'H-NMR spectrum of Crizotinib formate.

Figure 28 shows X-ray powder diffractogram of Crizotinib formate - amorphous form

FA1

Figure 29 shows ^-NMR spectrum of Crizotinib HC1. Figure 30 shows X-ray powder diffractogram of Crizotinib HC1 - crystalline Form

HI. Figure 31 shows DSC thermogram of Crizotinib HC1 - crystalline Form HI .

Figure 32 shows X-ray powder diffractogram of Crizotinib phosphate - crystalline Form P2.

Figure 33 shows DSC thermogram of Crizotinib phosphate - crystalline Form P2. Figure 34 shows X-ray powder diffractogram of Crizotinib succinate - crystalline

Form SA2.

Figure 35 shows DSC thermogram of Crizotinib succinate - crystalline Form SA2.

Figure 36 shows X-ray powder diffractogram of Crizotinib L-tartarate - crystalline Form T3. Figure 37 shows DSC thermogram of Crizotinib L-tartarate - crystalline Form T3.

Figure 38 shows X-ray powder diffractogram of Crizotinib tosylate - crystalline Form

Ts2.

Figure 39 shows DSC thermogram of Crizotinib tosylate - crystalline Form Ts2.

Figure 40 shows X-ray powder diffractogram of Crizotinib formate (analyzed at silicon-plates with imperfections) - crystalline Form FA2.

Figure 41 shows DSC thermogram of Crizotinib formate - crystalline Form FA2.

Figure 42 shows ^-NM spectrum of Crizotinib besilate.

Figure 43 shows X-ray powder diffractogram of Crizotinib besilate - crystalline Form

Bsl. Figure 44 shows DSC thermogram of Crizotinib besilate - crystalline Form Bsl .

Figure 45 shows 'H-NMR spectrum of Crizotinib ethane- 1,2-disulfonate.

Figure 46 shows X-ray powder diffractogram of Crizotinib ethane- 1,2-disulfonate - crystalline Form EDS1.

Figure 47 shows DSC thermogram of Crizotinib ethane- 1,2-disulfonate - crystalline Form EDS 1. Figure 48 shows H-NMR spectrum of Crizotinib L-malate.

Figure 49 shows X-ray powder diffractogram of Crizotinib L-malate - crystalline Form MAI .

Figure 50 shows DSC thermogram of Crizotinib L-malate - crystalline Form MAI. Figure 51 shows X-ray powder diffractogram of Crizotinib maleate - crystalline Form

M2.

Figure 52 shows DSC thermogram of Crizotinib maleate-crystalline Form M2. Figure 53 shows X-ray powder diffractogram of amorphous Crizotinib base. Figure 54 shows X-ray powder diffractogram of Crizotinib HC1 - crystalline Form H2.

Figure 55 shows DSC thermogram of Crizotinib HC1 - crystalline Form H2. Figure 56 shows X-ray powder diffractogram of Crizotinib HC1 - crystalline Form

H3.

Figure 57 shows DSC thermogram of Crizotinib HC1 - crystalline Form H3. Figure 58 shows 13C-NMR spectrum of Crizotinib HC1.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to salts of Crizotinib, as well as solid state forms thereof. Solid state properties of Crizotinib salts can be influenced by controlling the conditions under which the salts form. For example, Crizotinib phosphate, Crizotinib sulphate, Crizotinib acetate, Crizotinib maleate, Crizotinib fumarate, Crizotinib L-tartrate, Crizotinib citrate, Crizotinib p-toluene sulfonate, Crizotinib succinate Crizotinib formate, Crizotinib hydrochloride, Crizotinib besilate, Crizotinib ethane- 1 ,2-di-sulfonate and Crizotinib L-malate can be prepared by providing and/or manipulating reaction conditions, reagents and starting materials, and precipitation or crystallization conditions to obtained the salts and their solid state forms.

The present invention encompasses the following salts of Crizotinib: Crizotinib phosphate, Crizotinib sulphate, Crizotinib acetate, Crizotinib maleate, Crizotinib fumarate, Crizotinib L-tartrate, Crizotinib citrate, Crizotinib p-toluene sulfonate, Crizotimb succinate, Crizotinib formate, Crizotinib hydrochloride, Crizotinib besilate, Crizotinib ethane- 1.2- disulfonate and Crizotinib L-malate.

The present invention encompasses solid state forms of Crizotinib phosphate, Crizotinib sulphate, Crizotinib acetate, Crizotinib maleate, Crizotimb fumarate, Crizotinib L- tartrate, Crizotinib citrate, Crizotinib p-toluene sulfonate, Crizotinib succinate, Crizotinib formate, Crizotinib hydrochloride, Crizotinib besilate, Crizotinib ethane- 1.2-disulfonate and Crizotinib L-malate.

In some embodiments, salts and solid state forms of Crizotinib of the invention are substantially free of any other salts, polymorphic forms, or of specified polymorphic forms of Crizotinib, respectively. In any embodiment of the present invention, by "substantially free" is meant that the forms of the present invention contain 20% (w/w) or less, 10% (w/w) or less, 5% (w/w) or less, 2% (w/w) or less, particularly 1% (w/w) or less, more particularly 0.5% (w/w) or less, and most particularly 0.2% (w/w) or less of any other salts, polymorphs or of a specified polymorph of Crizotinib. In other embodiments, the salts and solid state forms of Crizotinib phosphate, Crizotinib sulphate, Crizotinib acetate, Crizotinib maleate, Crizotinib fumarate, Crizotinib L-tartrate, Crizotinib citrate, Crizotinib p-toluene sulfonate, Crizotinib succinate, Crizotinib formate Crizotinib hydrochloride, Crizotinib besilate, Crizotinib ethane- 1.2-disulfonate and Crizotinib L-malate of the invention contain from 1% to 20% (w/w), from 5% to 20% (w/w), or from 5% to 10% (w/w) of any other salts, solid state forms or of a specified polymorph of Crizotinib.

Depending on which other salt or solid state form they are compared with, the Crizotinib salts and solid state forms thereof of the present invention (particularly, phosphate, sulphate, acetate, maleate, fumarate, L-tartrate, citrate, p-toluene sulfonate, succinate, formate, hydrochloride, besilate, ethane- 1.2-disulfonate and L-malate salts) have advantageous properties selected from at least one of: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability (such as thermal and mechanical stability to polymorphic conversion, stability to dehydration and/or storage stability), low content of residual solvent, a lower degree of hygroscopicity, and advantageous processing and handling characteristics such as flowability, filterability compressibility, and bulk density.

A crystal form may be referred to herein as being characterized by graphical data "as depicted in" or "as substantially depicted in" a Figure. Such data include, for example, powder X-ray diffractograms and solid state NMR spectra. As is well-known in the art, the graphical data potentially provides additional technical information to further define the respective solid state form (a so-called "fingerprint") which cannot necessarily be described by reference to numerical values or peak positions alone. In any event, the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figures herein with graphical data generated for an unknown crystal form and confirm whether the two sets of graphical data are characterizing the same crystal form or two different crystal forms. A crystal form of a Crizotinib salt referred to herein as being characterized by graphical data "as depicted in" or "as substantially depicted in" a Figure will thus be understood to include any crystal forms of the Crizotinib salts

characterized with the graphical data having such small variations, as is well-known to the skilled person, in comparison with the Figure.

As used herein, the term "isolated" in reference to any of Crizotinib salts or solid state forms thereof of the present invention corresponds to Crizotinib salts or solid state forms thereof that is physically separated from the reaction mixture where the salts or solid state forms were formed. As used herein the term non-hygroscopic in relation to any of the salts and solid state forms of Crizotinib refers to less than 2% (w/w) adsorption of water, by the salt or solid state form of Crizotinib as determined, for example by TGA. Water can be, for example, atmospheric water.

As used herein, unless stated otherwise, the XRPD measurements are taken using copper Ka radiation wavelength 1.5406 A.

Solid state forms of Crizotinib comprise crystal forms, or crystalline forms, of Crizotinib. As used herein, solid state forms, crystal forms, crystalline forms, polymorphs and polymorphic forms are used interchangeably.

As used herein, and unless stated otherwise, the term "anhydrous" in relation to any of the crystalline Crizotinib salts relates to a crystalline Crizotinib salt which contains not more than 1.5% (w/w), or not more than 1% (w/w) of either water or organic solvents (bound and unbound) as measured by TGA or by Karl Fischer titration, for example, a Crizotinib salt which contains between about 0% to about 1.5% (w/w) or between about 0% to about 1% (w/w) of either water or organic solvents as measured by TGA or by Karl Fischer titration.

As used herein and unless indicated otherwise, the term "solvate" refers to a crystal form that incorporates a solvent in the crystal structure. When the solvent is water, the solvate is often referred to as a "hydrate." The solvent in a solvate may be present in either a stoichiometric or in a non-stoichiometric amount.

A thing, e.g., a reaction mixture, may be characterized herein as being at, or allowed to come to "room temperature", often abbreviated " T." This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located. Typically, room temperature is from about 20°C to about 30°C, or about 22°C to about 27°C, or about 25°C.

A process or step may be referred to herein as being carried out "overnight." This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is from about 8 to about 20 hours, or about 10-18 hours, typically about 16 hours.

As used herein, the term "reduced pressure" refers to a pressure of about 10 mbar to about 50 mbar.

As used herein, the terms "vol." or "volume" can be used to refer to ml per gram of the corresponding Crizotinib. For example, a statement that 0.5 g of Crizotinib is dissolved in ten volumes of a Solvent X would be understood to mean that the 0.5 g of Crizotinib was dissolved in 5 ml of Solvent X.

The present invention comprises salts of Crizotinib, in particular: phosphate, sulphate, acetate, maleate, fumarate, L-tartrate, citrate, p-toluene sulfonate, succinate, formate, hydrochloride, besylate, ethane- 1.2-disulfonate and L-malate salts. The above salts can be isolated.

In one embodiment, the present invention comprises Crizotinib phosphate salt. The Crizotinib phosphate salt can be characterized by an ^-NMR spectrum substantially as depicted in Figure 2. The Crizotinib phosphate may be in crystalline or amorphous form. The present invention comprises an amorphous form of Crizotinib phosphate, designated as Form PI. The amorphous form PI of Crizotinib phosphate salt can be characterized by an X-ray powder diffraction pattern as depicted in Figure 3. The present invention comprises a crystalline form of Crizotinib phosphate, designated as Form P2. Crystalline form P2 of Crizotinib phosphate salt can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 3.5,

14.1, 18.0, 23.9 and 26.5 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 32; and combinations of these data. Crystalline Form P2 of Crizotinib phosphate may be further characterized by an X-ray powder diffraction pattern having peaks at 3.5, 14.1, 18.0, 23.9 and 26.5 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at

11.2, 12.3, 16.6, 18.7 and 20.8 degrees two theta± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 33; and combinations of these data. Crystalline form P2 of Crizotinib phosphate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 3.5, 14.1, 18.0, 23.9 and 26.5 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 32.

In another embodiment, the present invention comprises Crizotinib sulphate salt. The Crizotinib sulphate salt can be characterized by an 'H-NMR spectrum substantially as depicted in Figure 4.

The Crizotinib sulphate may be in crystalline or amorphous form.

The present invention comprises a crystalline form of Crizotinib sulphate, designated as Form S 1. Crystalline form S 1 of Crizotinib sulphate salt can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 4.4, 10.2, 16.6, 18.4, 22.7 and 24.1 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 5; and combinations of these data. Crystalline Form SI of Crizotinib sulphate may be further characterized by an X-ray powder diffraction pattern having peaks at 4.4, 10.2, 16.6, 18.4, 22.7 and 24.1 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 6.7, 15.9, 17.6, 20.4 and 24.4 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 6; and combinations of these data.

Crystalline form S 1 of Crizotinib sulphate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 4.4, 10.2, 16.6, 18.4, 22.7 and 24.1 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 5.

The present invention also comprises an amorphous form of Crizotinib sulphate, designated as Form S2. Amorphous form S2 of Crizotinib sulphate can be characterized by X-ray powder diffraction pattern substantially as depicted in Figure 7. In another embodiment, the present invention comprises Crizotinib acetate salt. The

Crizotinib acetate salt can be characterized by an ^-NMR spectrum substantially as depicted in Figure 8.

The Crizotinib acetate may be in several solid state forms. The present invention comprises a solid state form of Crizotinib acetate, designated as Form Al. Form Al of Crizotinib acetate can be characterized by X-ray powder diffraction pattern substantially as depicted in Figure 9.

The present invention comprises a crystalline form of Crizotinib acetate, designated as Form A2. Crystalline form A2 of Crizotinib acetate salt can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 6.7, 13.4, 17.8, 22.2 and 24.0 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 10; and combinations of these data. Crystalline Form A2 of Crizotinib acetate may be further characterized by an X-ray powder diffraction pattern having peaks at 6.7, 13.4, 17.8, 22.2 and 24.0 degrees two theta± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 11.9, 14.1, 14.8, 18.6 and 22.9 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 11; and combinations of these data.

Crystalline form A2 of Crizotinib acetate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 6.7, 13.4, 17.8, 22.2 and 24.0 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 10. The present invention also comprises an amorphous form of Crizotinib Acetate, designated as Form A3. Amorphous form A3 of Crizotinib acetate can be characterized by X-ray powder diffraction pattern substantially as depicted in Figure 12.

In another embodiment, the present invention comprises Crizotinib succinate salt. The Crizotinib succinate salt can be characterized by an 'H-NMR spectrum substantially as depicted in Figure 13.

The Crizotinib succinate may be in crystalline or amorphous form.

The present invention comprises an amorphous form of Crizotinib succinate, designated as Form SAL Amorphous form SA1 of Crizotinib succinate salt can be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 14.

The present invention comprises a crystalline form of Crizotinib succinate, designated as Form SA2. Crystalline form SA2 of Crizotinib succinate salt can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 5.6, 15.1, 18.0, 21.9 and 27.3 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 34; and combinations of these data. Crystalline Form SA2 of Crizotinib succinate may be further characterized by a an X-ray powder diffraction pattern having peaks at 5.6, 15.1, 18.0, 21.9 and 27.3 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 6.4, 13.8, 16.8 20.4 and 31.7 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 35; and combinations of these data.

Crystalline form SA2 of Crizotinib succinate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 5.6, 15.1, 18.0, 21.9 and 27.3 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 34. In another embodiment, the present invention comprises Crizotinib maleate salt. The

Crizotinib maleate salt can be characterized by an ^-NMR spectrum substantially as depicted in Figure 15.

The Crizotinib maleate may be in several crystalline form.

The present invention comprises a crystalline form of Crizotinib maleate, designated as Form Ml . Crystalline form Ml of Crizotinib maleate can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 6.1, 9.3, 14.2, 18.7 and 28.2 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 16; and combinations of these data. Crystalline Form Ml of Crizotinib maleate may be further characterized by an X-ray powder diffraction pattern having peaks at 6.1, 9.3, 14.2, 18.7 and 28.2 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 12.3, 16.1, 16.9, 21.5 and 24.7 degrees two theta ± 0.2 degrees two theta; and combinations of these data.

Crystalline form Ml of Crizotinib maleate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 6.1, 9.3, 14.2, 18.7 and 28.2 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 1 .

The present invention comprises a crystalline form of Crizotinib maleate, designated as Form M2. Crystalline form M2 of Crizotinib maleate salt can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 7.8, 12.1, 15.9, 17.6 and 25.7 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 51; and combinations of these data. Crystalline Form M2 of Crizotinib maleate may be further characterized by an X-ray powder diffraction pattern having peaks at 7.8, 12.1, 15.9, 17.6 and 25.7 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 9.2, 17.0, 18.3, 19.9 and 24.1 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 52; and combinations of these data.

Crystalline form M2 of Crizotinib maleate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 7.8, 12.1, 15.9, 17.6 and 25.7 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 51.

In another embodiment, the present invention comprises Crizotinib fumarate salt. The Crizotinib fumarate salt can be characterized by an ^- MR spectrum substantially as depicted in Figure 17.

The present invention also provides solid state forms of Crizotinib fumarate. The present invention comprises a solid state form of Crizotinib fumarate, designated as Form Fl . Form Fl of Crizotinib fumarate can be characterized by X-ray powder diffraction pattern substantially as depicted in Figure 18.

The present invention comprises a crystalline form of Crizotinib fumarate, designated as Form F2. Crystalline form F2 of Crizotinib fumarate can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 9.8, 11.5, 20.1, 23.1 and 24.0 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 19; and combinations of these data. Crystalline Form F2 of Crizotinib fumarate may be further characterized by an X-ray powder diffraction pattern having peaks at 9.8, 11.5, 20.1, 23.1 and 24.0 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 15.9, 18.1, 19.0, 21.2 and

22.0 degrees two theta ± 0.2 degrees two theta; and combinations of these data.

Crystalline form F2 of Crizotinib maleate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 9.8, 11.5, 20.1 , 23.1 and 24.0 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 19.

In another embodiment, the present invention comprises Crizotinib L-tartrate salt. The Crizotinib L-tartrate salt can be characterized by an 'H-NMR spectrum substantially as depicted in Figure 20. The Crizotinib L-tartrate may be in crystalline or amorphous form.

The present invention comprises a crystalline form of Crizotinib L-tartrate, designated as Form Tl . Crystalline form Tl of Crizotinib L-tartrate can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 5.3, 9.6, 18.8, 21.9 and 26.3 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 21; and combinations of these data. Crystalline Form Tl of Crizotinib tartrate may be further characterized by an X-ray powder diffraction pattern having peaks at 5.3, 9.6, 18.8, 21.9 and 26.3 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 6.0, 10.7, 14.6, 15.3, 16.3 and

24.1 degrees two theta ± 0.2 degrees two theta; and combinations of these data. Crystalline form Tl of Crizotinib L-tartrate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 5.3, 9.6, 18.8, 21.9 and 26.3 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 21.

The present invention also comprises an amorphous form of Crizotinib L-tartrate, designated as Form T2. Amorphous form T2 of Crizotinib L-tartrate can be characterized by X-ray powder diffraction pattern substantially as depicted in Figure 22.

The present invention comprises a crystalline form of Crizotinib L-tartrate, designated as Form T3. Crystalline form T3 of Crizotinib L-tartrate salt can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 8.0, 11.4, 13.3, 18.2 and 22.3 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 36; and combinations of these data. Crystalline Form T3 of Crizotinib tartrate may be further characterized by an X-ray powder diffraction pattern having peaks at 8.0, 11.4, 13.3, 18.2 and 22.3 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 10.2, 14.2, 15.4, 21.5 and 26.4 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 37; and combinations of these data.

Crystalline form T3 of Crizotinib L-tartrate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 8.0, 11.4, 13.3, 18.2 and 22.3 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 36.

In another embodiment, the present invention comprises Crizotinib citrate salt. The Crizotinib citrate salt can be characterized by an 1 H-NMR spectrum substantially as depicted in Figure 23.

The Crizotinib citrate may be in an amorphous form.

The present invention comprises an amorphous form of Crizotinib citrate, designated as Form CI . Amorphous form CI of Crizotinib citrate can be characterized by X-ray powder diffraction pattern substantially as depicted in Figure 24.

In another embodiment, the present invention comprises Crizotinib p-toluene sulphonate salt. The Crizotinib p-toluene sulphonate salt can be characterized by an ^-NMR spectrum substantially as depicted in Figure 25. The present invention comprises a solid state form of Crizotinib p-toluene sulphonate, designated as Form Tsl. Form Tsl of Crizotinib p-toluene sulphonate can be characterized by X-ray powder diffraction pattern substantially as depicted in Figure 26.

The present invention comprises a crystalline form of Crizotinib p-toluene sulphonate, designated as Form Ts2. Crystalline form Ts2 of Crizotinib p-toluene sulphonate salt can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 4.5, 9.0, 13.9, 20.1 and 22.2 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 38; and combinations of these data. Crystalline Form Ts2 of Crizotinib p-toluene sulphonate may be further characterized by an X-ray powder diffraction pattern having peaks at 4.5, 9.0, 13.9, 20.1 and 22.2 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 4.3, 12.3, 17.8, 19.4 and 24.7 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 39; and combinations of these data.

Crystalline form Ts2 of Crizotinib p-toluene sulphonate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 4.5, 9.0, 13.9, 20.1 and 22.2 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 38.

In another embodiment, the present invention comprises Crizotinib formate salt. The Crizotinib formate salt can be characterized by an ^- MR spectrum substantially as depicted in Figure 27.

The Crizotinib formate may be in crystalline or amorphous form.

The present invention comprises an amorphous form of Crizotinib formate, designated as Form FA1. Amorphous form FA1 of Crizotinib formate can be characterized by X-ray powder diffraction pattern substantially as depicted in Figure 28. The present invention comprises a crystalline form of Crizotinib formate, designated as Form FA2. Crystalline form FA2 of Crizotinib formate salt can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 12.1, 14.7, 18.1, 24.1 and 28.5 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 40; and combinations of these data. Crystalline Form FA2 of Crizotinib formate may be further characterized by an X-ray powder diffraction pattern having peaks at 12.1, 14.7, 18.1, 24.1 and 28.5 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 3.6, 7.1, 20.8, 22.9 and 29.6 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 41; and combinations of these data.

Crystalline form FA2 of Crizotinib formate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 12.1, 14.7, 18.1, 24.1 and 28.5 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 40.

In another embodiment, the present invention comprises Crizotinib hydrochloride salt and crystalline forms of Crizotinib hydrochloride. The Crizotinib hydrochloride salt can be characterized by an ^-NMR spectrum substantially as depicted in Figure 29 or by 13C-NMR spectrum substantially as depicted in Figure 58 or by combination thereof.

Preferably, the Crizotinib hydrochloride salt is crystalline.

The present invention comprises a solid state form of Crizotinib hydrochloride, designated as Form HI . Form HI of Crizotinib hydrochloride can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 7.8, 14.4, 14.6, 17.5 and 25.7 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 30; and combinations of these data. Crystalline Form HI of Crizotinib hydrochloride may be further characterized by an X-ray powder diffraction pattern having peaks at 7.8, 14.4, 14.6, 17.5 and 25.7 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 20.1, 21.1, 22.7, 26.3 and 36.3 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 31; and combinations of these data.Crystalline Form HI of Crizotinib hydrochloride may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 7.8, 14.4, 14.6, 17.5 and 25.7 peaks degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 31.

Crizotinib hydrochloride form HI has advantageous properties. In particular, it appears to be a good intermediate in the preparation of form H2, which itself has

advantageous properties as further described herein. In addition, form HI is polymorphically stable, for example at temperature of 25°C and at a 60% relative humidity (RH) or a at temperature of 30°C and at a 65% RH. Furthermore form HI has a good pH independent aqueous solubility, compared to the Crizotinib base; amorphous Crizotinib hydrochloride; and other salts of Crizotinib, for example, succiante, L-tartrate, maleate and phosphate salts.

The present invention comprises a solid state form of Crizotinib hydrochloride, designated as Form H2. Form H2 of Crizotinib hydrochlorate can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 12.7, 18.8, 21.9, 24.1 and 24.6 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 54; and combinations of these data. Crystalline Form H2 of Crizotinib hydrochloride may be further characterized by an X-ray powder diffraction pattern having peaks at 12.7, 18.8, 21.9, 24.1 and 24.6 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 13.7, 18.4, 19.4, 23.0 and 27.8 degrees two theta± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 55; and combinations of these data.

Form H2 can have water content of about 4.3% (measured by Karl Fischer). In a preferred embodiment form H2 is a hydrate, more preferably a monohydrate. Crystalline Form H2 of Crizotinib hydrochloride may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 12.7, 18.8, 21.9, 24.1 and 24.6 peaks degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 54.

As discussed above, depending on which other solid state form it is compared with, crystalline Form H2 of Crizotinib hydrochloride may have advantageous properties selected from at least one of: chemical or polymorphic purity, flowability, solubility, dissolution rate, bioavailability, morphology or crystal habit, stability - such as chemical stability as well as thermal and mechanical stability with respect to polymorphic conversion, stability towards dehydration and/or storage stability, a lower degree of hygroscopicity, low content of residual solvents and advantageous processing and handling characteristics such as compressibility, and bulk density. Particularly, the crystalline Form H2 of Crizotinib hydrochloride is non- hygroscopic. It has less than 2% (w/w) adsorption of water during 48 hours exposure to 75% relative humidity (RH), as determined, for example, by TGA. The water adsorption has no impact on the crystalline form, as demonstrated by XRPD analysis, and is reversible, that is, subsequent exposure to RH of less than 75% results in desorption of the adsorbed water. Form H2 is also polymorphically stable, for example at temperature of 25°C and at a 60% relative humidity (RH); or a at temperature of 30°C and at a 65% RH; or a at temperature of 40°C and at a 75% RH.

The present invention comprises a solid state form of Crizotinib hydrochloride, designated as Form H3. Form H3 of Crizotinib hydrochlorate can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 5.9, 12.4, 16.5, 20.4 and 23.2 degrees two theta± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 56; and combinations of these data. Crystalline Form H3 of Crizotinib hydrochloride may be further characterized by an X-ray powder diffraction pattern having peaks at 5.9, 12.4, 16.5, 20.4 and 23.2degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 11.5, 15.3, 18.7, 21.1 and 30.5 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 57; and combinations of these data.

Crystalline Form H3 of Crizotinib hydrochloride may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 5.9, 12.4, 16.5, 20.4 and 23.2 peaks degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 56.

As discussed above, Crizotinib hydrochloride form H3 has advantageous properties. In particular, it appears to be a good intermediate in the preparation of form H2, which itself has advantageous properties as discussed above. In addition, form H3 is polymorphically stable, for example at temperature of 25°C and at a 60% relative humidity (RH) or a at temperature of 30°C and at a 65% RH. Furthermore form H3 has a good pH independent aqueous solubility, compared to the Crizotinib base; amorphous Crizotinib hydrochloride; and other salts of Crizotinib for example, succiante, L-tartrate, maleate and phosphate salts. In another embodiment, the present invention comprises Crizotinib besilate salt. The

Crizotinib besilate salt can be characterized by an ^- MR spectrum substantially as depicted in Figure 42.

The present invention comprises a solid state form of Crizotinib besilate, designated as Form BS I . Form BS 1 of Crizotinib besilate can be characterized one or more of the following: an X-ray powder diffraction pattern having peaks at 6.0, 11.0, 12.5, 16.8 and 20.1 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 43; and combinations of these data. Crystalline Form BS 1 of Crizotinib besilate may be further characterized by an X-ray powder diffraction pattern having peaks at 6.0, 11.0, 12.5, 16.8 and 20.1 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 5.3, 16.1, 19.5, 21.2 and 27.9 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 44; and combinations of these data.

Crystalline form BS1 of Crizotinib besilate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 6.0, 11.0, 12.5, 16.8 and 20.1 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 43.

In another embodiment, the present invention comprises Crizotinib ethane- 1,2-di sulfonate salt. The Crizotinib ethane- 1.2-di- sulfonate salt can be characterized by an ¾- NM spectrum substantially as depicted in Figure 45.

The present invention comprises a solid state form of Crizotinib efhane-1,2- disulfonate, designated as Form EDS1. Form EDS1 of Crizotinib ethane- 1.2-di- sulfonate can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 3.4, 11.3, 14.1, 20.6 and 26.4 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 46; and combinations of these data. Crystalline Form EDS1 of Crizotinib ethane- 1.2-disulfonate may be further characterized by an X-ray powder diffraction pattern having peaks at 3.4, 11.3, 14.1 , 20.6 and 26.4 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 12.3, 18.3, 21.0, 22.9 and 24.0 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 47; and combinations of these data.

Crystalline form EDS1 of Crizotinib ethane- 1.2-disulfonate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 3.4, 11.3, 14.1, 20.6 and 26.4degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 46.

In another embodiment, the present invention comprises Crizotinib L-malate salt. The Crizotinib L-malate salt can be characterized by an ^- MR spectrum substantially as depicted in Figure 48. The present invention comprises a solid state form of Crizotinib L-malate, designated as Form MAI . Form MAI of Crizotinib malate can be characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 4.2, 8.0, 14.0, 16.1 and 24.1 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 49; and combinations of these data. Crystalline Form MAI of

Crizotinib L-malate may be further characterized by an X-ray powder diffraction pattern having peaks at 4.2, 8.0, 14.0, 16.1 and 24.1 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 4.8, 10.1, 19.4, 23.0 and 25.5 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 50; and combinations of these data.

Crystalline form MAI of Crizotinib L-malate may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g., by an X-ray powder diffraction pattern having peaks at 4.2, 8.0, 14.0, 16.1 and 24.1 degrees two theta ± 0.2 degrees two theta and an X-ray powder diffraction pattern as depicted in Figure 49. The above described salts and solid state forms of Crizotinib can be used to prepare

Crizotinib base or other different salts of Crizotimb, as well as solid state forms thereof and/or pharmaceutical compositions and formulations.

The present invention encompasses a process for preparing other Crizotinib salts. The process comprises preparing any one of the Crizotinib salts and solid state forms of

Crizotinib, particularly, Crizotinib phosphate, Crizotinib sulphate, Crizotinib acetate,

Crizotinib maleate, Crizotinib fumarate, Crizotinib L-tartrate, Crizotinib citrate, Crizotinib p- toluene sulfonate, Crizotinib succinate, Crizotinib formate, Crizotinib hydrochloride, Crizotinib besilate, Crizotinib ethane- 1,2-disulfonate and Crizotimb L-malate by the processes of the present invention, and converting the salt to said other Crizotinib salts. The conversion can be done, for example, by a process comprising basifying any one or a combination of the above described Crizotinib salts and/or solid state forms thereof, and reacting the obtained Crizotinib base with an appropriate acid, to obtain the corresponding salt. Alternatively, the conversion can be done by salt switching, i.e., reacting a Crizotinib salt, with an acid having a pKa which is lower than the pKa of the acid of the first Crizotinib salt.

The present invention further encompasses 1) pharmaceutical compositions comprising any one or combination of the Crizotinib salts and solid state forms thereof, as described herein; 2) a pharmaceutical formulation comprising any one or combination of the Crizotinib salts and solid state forms thereof, and at least one pharmaceutically acceptable excipient; and 3) the use of any one or combination of the above-described Crizotinib salts and solid state forms thereof in the manufacture of pharmaceutical compositions, and 4) a method of treating a person suffering from cancer, comprising administration of an effective amount of any one of the pharmaceutical compositions and/or formulation comprising any one or more of the Crizotinib salts and solid state forms thereof described herein.

The present invention further comprises processes for preparing the above mentioned pharmaceutical formulations. The process comprises combining any one of the Crizotinib salts and solid state forms thereof of the present invention, with at least one pharmaceutically acceptable excipient.

The Crizotinib salts and/or solid state forms thereof of the present invention, as well as the pharmaceutical compositions and formulations comprising said Crizotinib salts and/or solid state forms can be used as a medicament. Preferably the medicament is used for the treatment of cancer.

Having thus described the invention with reference to particular preferred

embodiments and illustrative examples, those in the art can appreciate modifications to the invention as described and illustrated that do not depart from the spirit and scope of the invention as disclosed in the specification. The Examples are set forth to aid in

understanding the invention but are not intended to, and should not be construed to limit its scope in any way.

Nuclear magnetic resonance (NMR) spectroscopy method

Instrument: Varian Mercury 400 Plus NMR Spectrometer, Oxford AS, 400 MHz X-Ray Powder Diffraction method The sample was analyzed on a D8 Advance X-ray powder diffractometer (Bruker-

AXS, Karlsruhe, Germany). The sample holder was rotated in a plane parallel to its surface at 20 rpm during the measurement. Further conditions for the measurements are summarized in the table below. The raw data were analyzed with the program EVA (Bruker-AXS, Germany). The samples were layered onto a silicon specimen holder. Figure 1 shows the X- ray powder diffraction after analysis of the silicon specimen holder. standard measurement

radiation Οι Κα (λ = 1.5406 A)

source 38 kV / 40 mA

detector Vantec

detector slit variable

divergence slit v6

antiscattering slit v6

2Θ range / ° 2 < 2Θ < 55

step size / ° 0.017

Differential Scanning Calorimetrv (DSC)

Apparatus: Mettler Toledo DSC 822E coupled with a Mettler Toledo Gas-Flow-

Controller TS0800GC1 (Mettler-Toledo GmbH, GieBen, Germany)

Aluminium crucible:

Lid: perforated

Temperature range: 30°C to 300°C/350°C

Heating rate: 10°C/ min

Nitrogen flush: 50 mL / min

Software: STARe Version. 8.10

Interpretation: Endothermic modus

Examples

Reference examples

The starting Crizotinib free-base can be prepared according to US2008/293769, the content of which is incorporated by reference in its entirety.

Example 1: Preparation of Crizotinib phosphate (from methanol)

Crizotinib free-base (50 mg) was suspended in 1 mL methanol and heated to 50°C. Phosphoric acid (111 1M solution in methanol) was added at 50°C, and the resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage at 4°C for 7 days the residue was treated with isopropanol. The resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 49 mg of amorphous form PI of Crizotinib phosphate as a light beige powder.

Example 2: Preparation of Crizotinib phosphate (from DCM) Crizotinib free-base (50 mg) was suspended in 1 mL dichloromethane (DCM) and heated to 40 °C. Phosphoric acid (111 μΐ,; 1M solution in methanol) was added at 40°C. The resulting solution was cooled to 25°C and afterwards was stored at 4°C for 3 days. The volume was reduced and after storage for 3 days at 4°C, the residue was treated with isopropanol. The resultmg precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 50 mg of amorphous form PI of Crizotinib phosphate as a light beige powder.

Example 3: Preparation of Crizotinib sulphate (from methanol)

Crizotinib free-base (50 mg) was suspended in 1 mL methanol and heated to 50°C. Sulphuric acid (111 μί; 1M solution in methanol) was added at 50°C. The resulting solution was cooled to 25 °C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage at 4°C for 7 d, the resulting precipitate was isolated by filtration and washed with isopropanol (5 mL).The product was dried under reduced pressure at 40°C to yield 48 mg of crystalline form SI of Crizotinib sulphate as a light beige powder. Example 4: Preparation of Crizotinib sulphate (from DCM)

Crizotinib free-base (50 mg) was suspended in 1 mL DCM and heated to 40 °C.

Sulphuric acid (111 μL; 1M solution in methanol) was added at 40°C, the resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage for another 3 days at 4°C, isopropanol (0.5 ml ) was added. After storage for 7 days at 4°C, the resulting precipitate was isolated by filtration and washed with isopropanol (5 mL).The product was dried under reduced pressure at 40°C to yield 39 mg of amorphous form S2 of Crizotinib sulphate as a light beige powder.

Example 5: Preparation of Crizotinib acetate (from methanol)

Crizotinib free-base (50 mg) was suspended in 1 mL methanol and heated to 50°C. Acetic acid (111 μί; 1M solution in methanol) was added at 50°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage at 4°C for 7 days the residue was treated with isopropanol. Afterwards the volume was reduced almost to dryness and the reduced volume mixture was stored at 4°C for 5 days. The resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 25 mg of Crizotinib acetate form Al as a light beige powder. Example 6: Preparation of Crizotinib acetate (from DCM)

Crizotinib free-base (50 mg) was suspended in 1 mL DCM and heated to 40°C.

Acetic acid (111 μΐ,; 1M solution in methanol) was added at 40°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage for 3 days at 4°C, the residue was treated with isopropanol. After storage for 7 days at 4°C, the resulting precipitate was isolated by filtration and washed with isopropanol (5 mL).The product was dried under reduced pressure at 40°C to yield 29 mg of crystalline form A2 of Crizotinib acetate as a light beige solid.

Example 7: Preparation of Crizotinib succinate (from DCM) Crizotinib free-base (50 mg) was suspended in 1 mL DCM and heated to 40°C.

Succinic acid (111 μί; 1 M solution in methanol) was added at 40°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage for 3 days at 4°C, isopropanol (0.5 ml) was added. After storage for 7 days at 4°C, the resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 43 mg of amorphous form SA1 of Crizotinib succinate as a light beige powder.

Example 8: Preparation of Crizotinib maleate (from methanol)

Crizotinib free-base (50 mg) was suspended in 1 mL methanol and heated to 50°C. Maleic acid (111 L; 1M solution in methanol) was added at 50°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage at 4°C for 7 d the resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 51 mg of crystalline form Ml of Crizotinib maleate as a light beige powder.

Example 9: Preparation of Crizotinib maleate (from DCM) Crizotinib free-base (50 mg) was suspended in 1 mL DCM and heated to 40°C.

Maleic acid (111 μί; 1M solution in methanol) was added at 40°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage for 3 days at 4°C, the residue was treated with isopropanol. The resulting precipitate was isolated by filtration and washed with isopropanol (5 mL).The product was dried under reduced pressure at 40°C to yield 46 mg of crystalline form Ml of Crizotinib maleate as a light beige powder.

Example 10: Preparation of Crizotinib fumarate (from methanol)

Crizotinib free-base (50 mg) was suspended in 1 mL methanol and heated to 50°C. Fumaric acid (111 μΐ,; 1M solution in methanol) was added at 50°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage at 4°C for 7 d the resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 49 mg of Crizotinib fumarate form Fl as a light beige powder. Example 11: Preparation of Crizotinib fumarate (from DCM)

Crizotinib free-base (50 mg) was suspended in 1 mL DCM and heated to 40 °C. Fumaric acid (111 μί; 1M solution in methanol) was added at 40°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage for 3 days at 4°C, isopropanol (0.5 ml) was added. The resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 41 mg of crystalline form F2 of Crizotinib fumarate as a light beige powder.

Example 12: Preparation of Crizotinib L-tartarate (from methanol)

Crizotinib free-base (50 mg) was suspended in 1 mL methanol and heated to 50 °C. L-(+)-tartaric acid (111 μί; 1M solution in methanol) was added at 50°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage at 4°C for 7 days, the resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 48 mg of crystalline form Tl of Crizotinib L-(+)-tartarate as a light beige powder. Example 13: Preparation of Crizotinib L-tartarate (from DCM)

Crizotinib free-base (50 mg) was suspended in 1 mL DCM and heated to 40 °C. L- (+)-tartaric acid (111 μί; 1M solution in methanol) was added at 40°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage for 3 days at 4°C, the residue was treated with isopropanol. The resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 50 mg of amorphous form T2 of Crizotinib L-(+)-tartarate as a light beige powder.

Example 14: Preparation of Crizotinib citrate (from methanol)

Crizotinib free-base (50 mg) was suspended in 1 mL methanol and heated to 50 °C. Citric acid (111 μί; 1M solution in methanol) was added at 50°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage at 4°C for 7 days the residue was treated with isopropanol. The resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 52 mg of amorphous form CI of Crizotinib citrate as a light beige powder.

Example 15: Preparation of Crizotinib citrate (from DCM)

Crizotinib free-base (50 mg) was suspended in 1 mL DCM and heated to 40 °C. Citric acid (111 μL; 1M solution in methanol) was added at 40°C. The resulting solution was cooled to 25 °C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage for 3 days at 4°C, the residue was treated with isopropanol. The resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 58 mg of amorphous form CI of Crizotinib citrate as a light beige powder.

Example 16: Preparation of Crizotinib p-toluenesulphonate (from methanol) Crizotinib free-base (50 mg) was suspended in 1 mL methanol and heated to 50 °C. p-Toluenesulphonic acid monohydrate (111 μί; 1M solution in methanol) was added at 50°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and the residue was treated with isopropanol. The resulting precipitate was isolated after storage for 6 days at 4°C by filtration and washed with isopropanol (5 mL). The product was dried under reduced pressure at 40°C to yield 61 mg of Crizotinib p-toluenesulphonate form Tsl as a light beige powder.

Example 17: Preparation of Crizotinib p-toluenesulphonate (from DCM)

Crizotinib free-base (50 mg) was suspended in 1 mL DCM and heated to 40 °C. p-Toluenesulphonic acid monohydrate (111 μΤ; 1M solution in methanol) was added at 40°C. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 3 days. The volume was reduced and after storage for 3 days at 4°C, the residue was treated with isopropanol. After storage for 7 days at 4°C, the resulting precipitate was isolated by filtration and washed with isopropanol (5 mL).The product was dried under reduced pressure at 40°C to yield 57 mg of Crizotinib p-toluenesulphonate form Ts 1 as a light beige powder. Example 18: Preparation of Crizotinib formate (by freeze drying)

Crizotinb free base (200 mg) was suspended in 20 ml methanol/water (1 : 1 ) at room temperature. Formic acid (20 μΐ) was added to obtain a clear solution. The solution was frozen in liquid nitrogen and lyophilized over a period of 24h to give amorphous form FA1 of Crizotinib formate. Example 19: Preparation of Crizotinib acetate (by freeze drying)

Crizotinb free base (200 mg) was suspended in 20 ml methanol/water (1 :1) at room temperature. Acetic acid (40μ1) was added to obtain a clear solution. The solution was frozen in liquid nitrogen and lyophilized over a period of 24h to give amorphous form A3 of Crizotinib acetate. Example 20: Preparation of Crizotinib HC1- crystalline form HI

Crizotinib free-base (205 mg, 0.4 mmol) was suspended in 4 mL ethylacetate and heated to 50°C. Hydrochloric acid (420 μί; 1.25 M-solution in ethanol, 0.4 mmol, 1 eq. ) was added dropwise at 50°C. The resulting suspension was cooled to 25°C and afterwards stored at 25°C for 2 days. The resulting precipitate was isolated by filtration and washed with ethylacetate (5 mL).The product was dried for 5 days under normal pressure at 25°C to yield 183 mg of Crizotinib hydrochloride form HI (84.6%, 0.4 mmol) as a white powder.

Example 21: Preparation of Crizotinib phosphate- crystalline Form P2

Crizotinib free-base (202 mg, 0.4 mmol) was suspended in 3 mL THF and heated to 50°C. phosphoric acid (444 1 M-solution in methanol, 0.4 mmol, 1 eq.) was added at 50°C, the mixture was cooled to 25°C and afterwards stored at 4°C for 7 days. The resulting precipitate was isolated by filtration and washed with THF (4 mL). The product was dried under nonnal pressure at 25°C to yield 211 mg of Crizotinib phosphate, form P2 (86.6%, 0.4 mmol) as a light beige powder.

Example 22: Preparation of Crizotinib succinate- crystalline Form SA2 Crizotinib free-base (205 mg, 0.4 mmol) was suspended in 3 mL isopropanol and heated to 60°C. Succinic acid (1.35 mL; 0.33 M-solution in THF, 0.4 mmol, 1 eq.) was added at 60°C. The resulting suspension was cooled to 25°C and afterwards stored at 25°C for 3 hours. The resulting precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under normal pressure at 25°C to yield 239 mg of Crizotinib succinate, form SA2 (94.7%, 0.4 mmol) as a light beige powder.

Example 23: Preparation of Crizotinib L-(+)-tartrate- crystalline Form T3

Crizotinib free-base (203 mg, 0.4 mmol) was suspended in 2 mL ethanol/H20 (80:20) and heated to 50°C. L-(+)-tartaric acid (75 mg, 0.4 mmol, 1 eq.) was dissolved in 0.5 mL ethanol/H20 (80:20), heated to 50°C and added to the solution of the free base. The resulting mixture was heated to 60°C for 60 min and was then cooled to 25°C and stirred over night. The resulting precipitate was isolated by filtration and washed with ethanol (5 mL). The product was dried under normal pressure at 25°C to yield 187 mg of Crizotinib L-tartrate, form T3 (70.1%, 0.3 mmol) as a beige powder. Example 24: Preparation of Crizotinib tosylate- crystalline Form Ts2

Crizotinib free-base (503 mg, 1.1 mmol) was suspended in 20 mL ethanol and heated to 45°C. p-Toluenesu fonic acid (192 mg, 1.1 mmol, 1 eq.) was suspended in 5 mL ethanol, heated to 45°C and added at 45°C to the solution of the free base. The solution was cooled to 25°C, placed into a refrigerator (4-6°C) and stored for 17 days. The obtained precipitate was isolated by filtration and washed with isopropanol (5 mL). The product was dried under normal pressure at 25°C to yield 362 mg of Crizotinib tosylate, form Ts2 (52.4%, 0.6 mmol) as a beige powder.

Example 25: Preparation of Crizotinib formate- crystalline Form FA2

Crizotinib free-base (50 mg, 0.1 mmol) was suspended in 1.5 mL isopropylalcohol and heated to 60°C. Formic acid (111 μL, 1 M solution in methanol, 0.1 mmol, 1 eq.) was added at 60°C. The solution was cooled to 25°C and stored at 4°C for 3 days. The volume was reduced to 0.7 mL, diethylether (0.5 mL) was added and the mixture was stored at 4°C for 1 day. The solvent was evaporated, ethanol (1 mL) was added, the mixture was heated to 40°C and after cooling to 25°C, the mixture was stored at 25 °C for 7 days. The ethanol was evaporated, the residue was treated with ethylacetate (1 mL) and the mixture was stored at 4°C for 1 day. The resulting precipitate was isolated by filtration and washed with ethylacetate (3 mL). The product was dried under reduced pressure (30 mmbar) at 30°C to yield 35 mg of Crizotinib formate, form FA2 (63.5%, 0.1 mmol) as a light beige powder.

Example 26: Preparation of Crizotinib besilate

Crizotinib free-base (209 mg, 0.4 mmol) was suspended in 3 mL THF and heated to 50°C. Benzenesulfonic acid (444 μL, 1 M solution in methanol, 0.1 mmol, 1 eq.) was added at 50°C. The solution was cooled to 25°C, the volume was reduced to 1 mL and stored at 4°C for 4 days. The resulting precipitate was isolated by filtration and washed with THF (5 mL). The product was dried under normal pressure at 25°C to yield 195 mg of Crizotinib besilate, form BS1 (72.2%, 0.3 mmol) as a light beige powder. Example 27: Preparation of Crizotinib ethane-l,2-disulphonate

Crizotinib free-base (204 mg, 0.4 mmol) was suspended in 3 mL THF and heated to 50°C. Ethane- 1,2-disulfonic acid (444 μL, 1 M solution in methanol, 0.1 mmol, 1 eq.) was added at 50°C. The suspension was slowly cooled to 25°C and stored at 4°C for 2 days. The resulting precipitate was isolated by filtration and washed with THF (4 mL). The product was dried under normal pressure at 25°C to yield 253 mg of Crizotinib ethane- 1 ,2- disulfonate, form EDS1 (88.9%, 0.4 mmol) as a beige powder.

Example 28: Preparation of Crizotinib L-malate

Crizotinib free-base (506 mg, 1.1 mmol) was suspended in 10 mL methanol and heated to 45°C. L-Malic acid (155 mg, 1.1 mmol, 1 eq.) was dissolved in 2 mL methanol, heated to 45°C and added dropwise at 45°C to the solution of the free base. Afterwards, isopropylalcohol (8 mL) was added. The solution was cooled to 25°C and stored at 4°C for 9 days. The solvent was evaporated to 5 mL and the solution was stored at 4°C for 4 days. The resulting precipitate was isolated by filtration and washed with isopropylalcohol (5 mL). The product was dried under normal pressure at 25°C to yield 531 mg of Crizotinib L-malate (81.8%, 0.9 mmol) as a beige powder.

Example 29: Preparation of Crizotinib maleat- crystalline Form M2

Crizotinib free-base (202 mg, 0.4 mmol) was suspended in 3 mL THF and heated to 50 °C. Maleic acid (444 μΤ; 1 M-solution in methanol, 0.4 mmol, 1 eq.) was added at 50°C, the resulting suspension was cooled to 25 DC and afterwards stored at 4°C for 2 days. The resulting precipitate was isolated by filtration and washed with THF (5 mL).The product was dried under normal pressure at 25°C to yield 137 mg of crystalline Crizotinib maleate, Form M2 (54.5%, 0.2 mmol) as a light beige powder.

Example 30: Preparation of Crizotinib maleate Form Ml

Crizotinib free-base (204 mg, 0.4 mmol) was suspended in 0.5 mL ethanol/H20 (80:20) and heated to 50 °C. Maleic acid (53 mg; 0.4 mmol, 1 eq.) was dissolved in 2 mL ethanol/H20 (80:20), heated to 50°C and added at 50°C to the solution of Crizotinib free base. The resulting solution was cooled to 25°C and afterwards stored at 4°C for 4 days. The resulting precipitate was isolated by filtration and washed with ethanol (5 mL). The product was dried under normal pressure at 25°C to yield 123 mg of crystalline Crizotinib maleate, Form Ml (48.9%, 0.2 mmol) as a light beige powder.

Example 31: Preparation of Crizotinib maleate Form Ml

Crizotinib free-base (1,01 g, 2.2 mmol) was suspended in 15 mL methanol and heated to 45 °C. Maleic acid (265 mg; 2.2 mmol, 1 eq.) was dissolved in 7 mL methanol, heated to 45°C and added at 45°C to the solution of Crizotinib free base. Afterwards isopropanol (15 mL) was added to this solution. The resulting suspension was cooled to 25 °C and afterwards stored at 25°C over night. The resulting precipitate was isolated by filtration and washed with isopropanol (10 mL).The product was dried under normal pressure at 25°C to yield 1.12 g of Crizotinib maleate, Form Ml (89.0%, 2.0 mmol) as a beige powder.

Example 32: Preparation of Preparation of amorphous Crizotinib base Crizotinib free-base form I (200 mg; 0.4 mmol) was dissolved in 12 mL tert- butanol/water (6/4). The solution was frozen in liquid nitrogen and lyophilized over a period of 24h to give the amorphous Crizotinib base.

Example 33: Preparation of Crizotinib HC1- crystalline form H2

Crizotinib (500 mg, 1.1 mmol) was suspended in 10 mL ethyl acetate at 50°C. 1.25 M HC1 in ethanol (1.1 mL, 1.1 mmol) was added dropwise to this suspension. After complete addition the mixture was stored in the fridge over night. A clear solution with a sticky solid was obtained. This was aged opened under the hood at rt for one day. The sticky solid was crushed with a spatula and the solid was filtrated and washed with 5 mL ethyl acetate. The obtained brownish solid was dried in an exsiccator (rt/25mbar) over night to yield 470 mg (87%) Crizotinib hydrochloride as form H2. Example 34: Preparation of Crizotinib HCl- crystalline form H3

Crizotinib (1 g, 2.2 mmol) was suspended in 14 mL acetone and heated under stirring to 50°C. 1.25 M HCl in ethanol (2.1 mL, 2.1 mmol) was added dropwise very slow to this suspension. After complete addition the mixture was cooled down to rt and stirred at rt over night. The solid was filtrated and washed with 4 mL acetone. The solid was dried at 75°C/25mbar for two days to yield 840 mg (77%) Crizotinib hydrochloride from H3 as a brownish solid.

Example 35: The pH independent aqueous solubility

Solubility of Crizotinib salts was determined at 37°C using a magnetic stirrer for parallel synthesis at 150 rpm. About 250 mg of each salt were suspended in 0.1 N HCl (pH =1.2), acetate buffer pH 4.5 (USP) and phosphate buffer ph 6.8 (USP). After 1 h and 24 h, a sample was filtered through a PTFE filter 0.2 μηι and analyzed via HPLC.

Figure imgf000034_0001

Claims

We claim:
1. Crizotinib hydrochloride salt in crystalline form.
2. A crystalline form of Crizotinib hydrochloride salt according to claim 1, designated as Form H2, characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 12.7, 18.8, 21.9, 24.1 and 24.6 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 54; and combinations of these data.
3. The crystalline form of Crizotinib hydrochloride salt according to claim 2, further characterized by an X-ray powder diffraction pattern having peaks at 12.7, 18.8, 21.9, 24.1 and 24.6 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 13.7, 18.4, 19.4, 23.0 and 27.8 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 55; and combinations of these data.
4. A crystalline form of Crizotinib hydrochloride salt according to claim 1, designated as Form HI, characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 7.8, 14.4, 14.6, 17.5 and 25.7 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 30; and combinations of these data.
5. The crystalline form of Crizotinib hydrochloride salt according to claim 4, further characterized by an X-ray powder diffraction pattern having peaks at 7.8, 14.4, 14.6, 17.5 and 25.7 degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 20.1, 21.1, 22.7, 26.3 and 36.3 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 31; and combinations of these data.
6. A crystalline form of Crizotinib hydrochloride salt according to claim 1, designated as Form H3, characterized by one or more of the following: an X-ray powder diffraction pattern having peaks at 5.9, 12.4, 16.5, 20.4 and 23.2 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 56; and combinations of these data.
7. The crystalline form of Crizotinib hydrochloride salt according to claim 6, further characterized by an X-ray powder diffraction pattern having peaks at 5.9, 12.4, 16.5, 20.4 and
23.2degrees two theta ± 0.2 degrees two theta and also having any one, two, three, four or five additional peaks at 11.5, 15.3, 18.7, 21.1 and 30.5 degrees two theta ± 0.2 degrees two theta; a DSC curve substantially as depicted in Figure 57; and combinations of these data.
8. A pharmaceutical formulation comprising the crystalline crizotinib hydrochloride salt according to any one of claims 1-7.
9. A pharmaceutical formulation comprising the crystalline crizotinib hydrochloride salt according to any one of claims 1-7, or the pharmaceutical composition according to claim 8, and at least one pharmaceutically acceptable excipient.
10. Use of the crystalline form of Crizotinib hydrochloride salt according to any one of claims 1-7 in the manufacture of a pharmaceutical composition.
11. A process for preparing the pharmaceutical formulation according to claim 9 comprising combining the crystalline form of Crizotinib hydrochloride salt according to any one of claims 1 -7, or the pharmaceutical composition according to claim 8, with at least one pharmaceutically acceptable excipient.
12. The crystalline form of Crizotinib hydrochloride salt according to any one of claims 1-7 or a pharmaceutical composition according to claim 8 or the formulation according to claim 9 for use as a medicament.
13. The crystalline Crizotinib hydrochloride salt according to any one of claims 1-7, the pharmaceutical composition according to claim 8, or the formulation according to claim 9 for use in treating a person suffering from cancer.
14. A method of treating a person suffering from cancer, comprising administering a pharmaceutically effective amount of a crystalline Crizotinib hydrochloride salt according to any one of claims 1-7, a pharmaceutical composition according to claim 8, or a formulation according to claim 9.
15. Use of the crystalline form of Crizotinib hydrochloride salt according to any one of claims 1-7 for use in the preparation of Crizotinib free-base.
16. A process for preparing Crizotinib free-base comprising preparing the crystalline form of Crizotinib hydrochloride salt according to any one of claims 1-7 and converting it to crizotinib free-base.
17. The process according to claim 16, wherein the conversion is accomplished by a process comprising basifying a solution of the crystalline fonn of Crizotinib hydrochloride salt according to any one of claims 1-7 to produce Crizotinib free-base.
18. Use of the crystalline crystalline form of Crizotinib hydrochloride salt according to any one of claims 1 -7 in the preparation of a Crizotinib salt and solid state forms of
Crizotinib selected from: Crizotinib phosphate, Crizotinib sulphate, Crizotinib acetate, Crizotinib maleate, Crizotinib fumarate, Crizotinib L-tartrate, Crizotinib citrate, Crizotinib p- toluene sulfonate, Crizotinib succinate, Crizotinib formate, Crizotinib besilate, Crizotmib ethane- 1 ,2-disulfonate, Crizotinib L-malate and combinations thereof.
19. A process for preparing Crizotinib salt and solid state forms of Crizotinib selected from: Crizotinib phosphate, Crizotinib sulphate, Crizotinib acetate, Crizotinib maleate, Crizotinib fumarate, Crizotinib L-tartrate, Crizotinib citrate, Crizotinib p-toluene sulfonate, Crizotinib succinate, Crizotinib formate, Crizotinib besilate, Crizotinib ethane- 1,2- disulfonate, Crizotinib L-malate and combinations thereof, comprising preparing the crystalline form of Crizotinib hydrochloride salt according to any one of claims 1 -7 and converting it to said crizotinib salt. 20. The process according to claim 19, wherein the conversion is accomplished by a process comprising basifying a solution of the crystalline fonn of Crizotinib hydrochloride salt according to any one of claims 1 -7 to produce Crizotinib free-base, and reacting the obtained Crizotinib free-base with an appropriate acid to obtain the corresponding salt.
PCT/US2013/043113 2012-05-29 2013-05-29 Crizotinib hydrochloride salt in crystalline WO2013181251A9 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201261652708 true 2012-05-29 2012-05-29
US61/652,708 2012-05-29
US201361752673 true 2013-01-15 2013-01-15
US61/752,673 2013-01-15

Publications (2)

Publication Number Publication Date
WO2013181251A1 true true WO2013181251A1 (en) 2013-12-05
WO2013181251A9 true WO2013181251A9 (en) 2014-03-13

Family

ID=48577949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/043113 WO2013181251A9 (en) 2012-05-29 2013-05-29 Crizotinib hydrochloride salt in crystalline

Country Status (1)

Country Link
WO (1) WO2013181251A9 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014203177A1 (en) * 2013-06-18 2014-12-24 Shilpa Medicare Limited Amorphous (r) -3- [1- (2, 6-dichloro-3-fluorophenyl) methoxy] -5- [1- (piperidin-4- yl) -1h-pyrazol-4-yl] pyridin-2-amine
WO2015107553A3 (en) * 2014-01-15 2015-11-26 Laurus Labs Private Limited A process for the preparation of crizotinib or an acid addition salt thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021884A2 (en) 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006021881A2 (en) 2004-08-26 2006-03-02 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2007066185A2 (en) 2005-12-05 2007-06-14 Pfizer Products Inc. Polymorphs of a c-met/hgfr inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021884A2 (en) 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006021881A2 (en) 2004-08-26 2006-03-02 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2007066185A2 (en) 2005-12-05 2007-06-14 Pfizer Products Inc. Polymorphs of a c-met/hgfr inhibitor
US20080293769A1 (en) 2005-12-05 2008-11-27 Pfizer Inc. Polymorphs of a C-Met/Hgfr Inhibitor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014203177A1 (en) * 2013-06-18 2014-12-24 Shilpa Medicare Limited Amorphous (r) -3- [1- (2, 6-dichloro-3-fluorophenyl) methoxy] -5- [1- (piperidin-4- yl) -1h-pyrazol-4-yl] pyridin-2-amine
WO2015107553A3 (en) * 2014-01-15 2015-11-26 Laurus Labs Private Limited A process for the preparation of crizotinib or an acid addition salt thereof

Also Published As

Publication number Publication date Type
WO2013181251A9 (en) 2014-03-13 application

Similar Documents

Publication Publication Date Title
US20090048448A1 (en) Salts of cynnamide compound or solvates thereof
WO2007015871A1 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2005023192A2 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2011071821A1 (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof.
WO2011163222A1 (en) Nilotinib salts and crystalline forms thereof
WO2012027543A1 (en) Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
US20060223817A1 (en) Crystalline imatinib base and production process therefor
WO2013052157A1 (en) Crystalline forms of afatinib di-maleate
WO2007015870A2 (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2010117738A2 (en) Solid state forms of sitagliptin salts
WO2010133976A2 (en) Substantially pure imatinib or a pharmaceutically acceptable salt thereof
WO2009093127A2 (en) Substantially pure and a stable crystalline form of bosentan
US20070203178A1 (en) Crystalline solvates of apixaban
US20090192200A1 (en) Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
WO2013078361A1 (en) Solid state forms of vilazodone and vilazodone hydrochloride
WO2012068441A2 (en) Intedanib salts and solid state forms thereof
WO2006030449A1 (en) Crystalline alfuzosin base
WO2012082972A1 (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
WO2012044595A1 (en) Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
US20120083517A1 (en) Polymorphs of saxagliptin hydrochloride and processes for preparing them
WO2012015999A2 (en) Process for the preparation of imatinib mesylate
CN1845917A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicam
WO2006131338A2 (en) Crystalline solvate of omeprazole sodium
US20080167477A1 (en) Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
US20080207904A1 (en) Imatinib base, and imatinib mesylate and processes for preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13727780

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13727780

Country of ref document: EP

Kind code of ref document: A1